

Journal of Pharmaceutical Sciences



MARCH 1976

VOLUME 65 NUMBER 3

MARY H. FERGUSON
Editor

L. LUAN CORRIGAN
Assistant Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LELAND J. ARNEY
Publications Director

EDITORIAL ADVISORY BOARD

JOHN AUTIAN	HARRY B. KOSTENBAUDER
LYNN R. BRADY	CARL J. LINTNER, JR.
WILLIAM O. FOYE	DAVID E. MANN, JR.
WILLIAM J. JUSKO	GERALD J. PAPARIELLO

The *Journal of Pharmaceutical Sciences* is published monthly by the American Pharmaceutical Association at 2215 Constitution Ave., N.W., Washington, DC 20037. Second-class postage paid at Washington, D.C., and at additional mailing office.

All expressions of opinion and statements of supposed fact appearing in articles or editorials carried in this journal are published on the authority of the writer over whose name they appear and are not to be regarded as necessarily expressing the policies or views of the American Pharmaceutical Association.

Offices—Editorial, Advertising, and Subscription Offices: 2215 Constitution Ave., N.W., Washington, DC 20037. Printing Offices: 20th & Northampton Streets, Easton, PA 18042

Annual Subscriptions—United States and foreign, industrial and government institutions \$50, educational institutions \$50, individuals *for personal use only* \$30; single copies \$5. All foreign subscriptions add \$5 for postage. Subscription rates are subject to change without notice. Members of the American Pharmaceutical Association may elect to receive the *Journal of Pharmaceutical Sciences* as a part of their annual \$60 (foreign \$65) APhA membership dues.

Claims—Missing numbers will not be supplied if dues or subscriptions are in arrears for more than 60 days or if claims are received more than 60 days after the date of the issue, or if loss was due to failure to give notice of change of address. The Association cannot accept responsibility for foreign delivery when its records indicate shipment has been made.

Change of Address—Members and subscribers should notify at once both the Post Office and the American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037, of any change of address.

© Copyright 1976, American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037; all rights reserved.

THE SUM OF ITS PARTS

Mitosis, or cell division to form two daughter cells, constitutes one of the most basic and elementary of life processes. From time to time a comparable phenomenon is encountered in other aspects of life and society, including that peculiar organizational structure called "government" that man has established for the purpose of providing an orderly system for the operation of society.

A primary feature of legislation recently introduced in the U.S. Senate under the co-sponsorship of Senators Kennedy and Javits would have the net effect of mitosis on what is now the federal Food and Drug Administration. The pertinent bills would create a Drug and Devices Administration and a Food and Cosmetic Administration. Each would be staffed, budgeted, operated, and administered completely independently of the other, in contrast to the present arrangement whereby all of these functions and responsibility fall within the purview of the FDA under the sole direction of the Commissioner of Food and Drugs.

Much can be said in favor of such a split:

(a) Smaller specialized agencies are more responsive and can be mobilized faster and more effectively;

(b) Narrowed responsibilities would enable greater concentration of attention and enhance the focusing of available resources;

(c) Foods and drugs are quite different commodities, having entirely different purposes and presenting basically different problems;

(d) The technical and scientific programs for surveillance of foods and of drugs have very little in common so that testing facilities and personnel have limited interchangeability; and

(e) Separate allocation of budget, manpower, and other resources would clarify the commitment actually made to each area, thereby facilitating administrative review and congressional oversight in terms of expended costs *versus* achieved results.

But by the same token, much also can be said in favor of a single unified agency:

(a) A single large agency has more visibility and political clout than several fragmented smaller ones;

(b) Internal communications are more simple, direct, and prompt within a single agency than between dual agencies;

(c) Despite their obvious differences, foods and drugs do have definite areas of overlap, calling for a unified, comprehensive approach—for example, drugs in animal feeds and vitamin products of various potencies;

(d) In the event of major emergencies, such as the botulism incident, even specialized inspectors can contribute valuable, alternate duty in a relatively unfamiliar area of activity; and

(e) Destructive interagency rivalries and competition for limited funds are eliminated while flexibility of resource allocation is at least possible, even though applicable opportunities may be relatively limited.

Hence, the proposal that FDA undergo karyokinesis is a complex matter requiring considerable analysis before a judgment can be rendered to the effect that it would be either beneficial or detrimental. Basically, the determination must come down to an assessment of whether in this case the whole is greater than, or less than, the sum of its component parts.

In announcing their joint bill, Senators Kennedy and Javits stated that they would be soliciting advice, recommendations, and opinions from a wide variety of sources before proceeding further with their proposal. They are to be commended for this attitude because it is evident that not only is the preferred route not yet clear but also that the decision eventually made will have a major impact on the public health and welfare. We add our sincere hope that the ultimate outcome will prove both successful and beneficial to all concerned.

—EGF